Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

The microbiome and athletic performance: scientific insights and investment landscape

Engineering the gut: Endure Biotherapeutics secures NIH funding for groundbreaking FAP therapy

Mice study shows how gut bacteria help train immune cells to prevent inflammation

A $2.5 billion catalyst: how the Gates Foundation is redefining women’s health innovation—with the microbiome in the spotlight

Unravelling the secrets of protein glycosylation

Do we need a Ministry of Microbes?

Latest News